Obesity-drug research is moving beyond single-receptor GLP-1 agonism toward dual, triple and multi-target approaches that combine incretin, glucagon, amylin and other metabolic pathways.
By 2026, several compounds have progressed substantially: retatrutide has reported pivotal Phase 3 results, survodutide and MariTide are in Phase 3 development, mazdutide has received regulatory approval in China, and Novo Nordisk’s amycretin—now called zenagamtide—has entered Phase 3 obesity development.
This guide compares these programmes by mechanism, development stage and evidence rather than treating them as interchangeable “weight-loss peptides.”
Why Is Everyone Talking About the Next Generation of Obesity Peptides?
Interest in obesity peptides has expanded dramatically over the past few years, but the conversation has recently shifted from traditional GLP-1 therapies to a new wave of investigational compounds.
One reason is the growing global burden of obesity. According to the World Health Organization (WHO), more than 1 billion people worldwide were living with obesity in 2022, making it one of the most significant public health challenges today. At the same time, the International Diabetes Federation (IDF) estimates that approximately 589 million adults were living with diabetes in 2024, with projections rising to 853 million by 2050.
As these numbers continue to increase, researchers are searching for new ways to better understand how appetite, metabolism, and energy balance are regulated.
GLP-1 receptor agonists established the importance of incretin pathways in obesity research. Tirzepatide then demonstrated the clinical relevance of dual GIP/GLP-1 receptor agonism, while newer programmes are testing glucagon, amylin and other complementary mechanisms.
Today, the focus has shifted again. Pharmaceutical companies, including Eli Lilly, Novo Nordisk, Amgen, Boehringer Ingelheim, and Innovent Biologics, are investing heavily in compounds that activate multiple receptors at the same time. Rather than asking whether one pathway is enough, researchers are now investigating how several interconnected metabolic pathways may work together.
This shift has led to growing interest in compounds such as:
- Retatrutide — GIP / GLP-1 / glucagon triple agonist
- Mazdutide — GLP-1 / glucagon dual agonist
- Survodutide — glucagon / GLP-1 dual agonist
- MariTide — GLP-1 receptor agonism + GIP receptor antagonism via an antibody–peptide conjugate
- Zenagamtide (formerly amycretin) — GLP-1 / amylin receptor agonist
Together, these programmes illustrate the shift toward multi-pathway obesity pharmacology, although they differ substantially in molecular format, receptor activity and regulatory status.
How Obesity Peptide Research Has Evolved
The science behind obesity peptides has progressed rapidly over the past decade. Rather than replacing previous discoveries, each generation has built upon earlier research to explore increasingly complex biological pathways.
Evolution of Obesity Peptide Research
| Generation | Examples | Main Research Focus |
| First Generation | GLP-1 receptor agonists | Appetite regulation and glucose-related signaling |
| Second Generation | Tirzepatide | Dual agonist (GLP-1 + GIP) |
| Third Generation | Retatrutide | Triple agonist (GLP-1 + GIP + glucagon) |
| Emerging multi-target programmes | MariTide, Zenagamtide, Survodutide | Multi-pathway metabolic biology |
This generational framework is editorial rather than a formal pharmacological classification.
First Generation: GLP-1 Research
The first major breakthrough came from GLP-1 receptor agonists, which helped researchers better understand appetite signaling, satiety, and glucose regulation. These compounds demonstrated that targeting a single hormone pathway could meaningfully influence metabolic processes and sparked widespread interest in peptide-based obesity research.
Second Generation: Dual Agonists
The next step involved activating two biological pathways instead of one.
Tirzepatide combines GLP-1 and GIP receptor activity, allowing researchers to investigate how multiple incretin hormones work together to regulate appetite, nutrient sensing, and metabolic communication. This dual-pathway approach significantly expanded scientific interest in combination peptide therapies.
Third Generation: Triple Agonists
Researchers then introduced an additional biological pathway through compounds such as Retatrutide.
By combining GLP-1, GIP, and glucagon receptor activity, triple agonists allow scientists to study appetite regulation alongside energy expenditure and broader metabolic signaling. Retatrutide has now reported multiple Phase 3 results. In TRIUMPH-1, Lilly reported an average 28.3% body-weight reduction at 80 weeks with the 12 mg group under the efficacy estimand.
The Emerging Generation
Research continues to move beyond traditional incretin biology.
New investigational programmes, including MariTide, Zenagamtide and Survodutide, are exploring alternative combinations of metabolic pathways, longer-acting formulations, and entirely new biological targets. While many remain in clinical development, they illustrate how rapidly obesity peptide research continues to evolve.
Are All Next-Generation Obesity Compounds Peptides?
Not exactly. “Obesity peptides” is a useful search term, but modern obesity pipelines include several molecular formats.
| Compound | Molecular / Mechanistic Format |
| Retatrutide | Unimolecular peptide triple receptor agonist |
| Mazdutide | Peptide GLP-1/glucagon dual receptor agonist |
| Survodutide | Peptide glucagon/GLP-1 dual receptor agonist |
| Zenagamtide | Unimolecular peptide GLP-1/amylin receptor agonist |
| MariTide | Antibody–peptide conjugate with GLP-1R agonism and GIPR antagonism |
These programmes often appear together under terms such as “next-generation obesity peptides,” but their molecular structures and pharmacological strategies are not equivalent.
What Makes the New Generation Different?
One of the biggest changes in modern obesity research is that scientists are no longer focusing on a single biological pathway.
Instead, many of today’s investigational peptides are designed to activate multiple signaling systems that naturally work together to regulate appetite, metabolism, energy balance, and nutrient processing. This broader approach reflects a growing understanding that obesity is influenced by a complex network of hormones rather than one receptor alone.
GLP-1 Peptides
GLP-1 receptor agonists transformed metabolic research by demonstrating how a single hormone pathway could influence appetite and satiety.
Researchers continue studying GLP-1 because it plays a central role in:
- Appetite signaling
- Satiety communication
- Glucose-related pathways
- Gastric emptying
- Nutrient processing
Although GLP-1 remains an important target, researchers now recognize that additional biological pathways may also contribute to metabolic regulation.
Dual Agonists
Dual agonists combine GLP-1 with another complementary hormone pathway.
For example, Tirzepatide activates both GLP-1 and GIP receptors. Researchers study this combination because GIP participates in nutrient sensing and metabolic communication, providing insights beyond GLP-1 activity alone.
The success of dual agonists encouraged researchers to explore even more comprehensive metabolic approaches.
Triple Agonists
Triple agonists represent one of the newest directions in obesity peptide research.
Retatrutide combines:
- GLP-1
- GIP
- Glucagon
Adding glucagon receptor activity has generated considerable scientific interest because researchers are investigating its potential role in energy expenditure, fat oxidation pathways, liver metabolism, and overall metabolic flexibility.
This multi-pathway approach is one of the main reasons Retatrutide Peptide Research Guide has become one of the most discussed investigational peptides today.
Multi-Target and Alternative-Mechanism Programmes
Not all newer obesity candidates simply add another receptor agonist. Some use different receptor-direction combinations or molecular formats. MariTide, for example, combines GLP-1 receptor agonism with GIP receptor antagonism, while zenagamtide combines GLP-1 and amylin receptor agonism.
Comparing the Generations of Obesity Peptides
| Peptide Type | Pathways Studied | Examples | Current Research Focus |
| GLP-1 Agonists | GLP-1 | Earlier GLP-1 therapies | Appetite regulation |
| Dual Agonists | GLP-1 + GIP or GLP-1 + Glucagon | Tirzepatide, Mazdutide, Survodutide | Appetite, nutrient signaling, metabolism |
| Triple Agonists | GLP-1 + GIP + Glucagon | Retatrutide | Appetite, metabolism, energy expenditure |
| Emerging Multi-Target Therapies | GLP-1R agonism + GIPR antagonism (MariTide); GLP-1 + amylin receptor agonism (Zenagamtide) | MariTide, Zenagamtide | Next-generation metabolic biology |
You might also like: Retatrutide vs Tirzepatide
Major Next-Generation Obesity Programmes in 2026
Several programmes now have substantial late-stage clinical evidence or regulatory milestones. Their development stages and mechanisms differ, so they should be compared descriptively rather than ranked.
Retatrutide
Retatrutide is an investigational GIP, GLP-1 and glucagon triple receptor agonist developed by Lilly. In TRIUMPH-1, Lilly reported average body-weight reductions of 19.0%, 25.9% and 28.3% at 80 weeks across the 4 mg, 9 mg and 12 mg groups under the efficacy estimand.
In a prespecified extension among participants with baseline BMI ≥35 who continued 12 mg, Lilly reported an average 30.3% reduction at 104 weeks.
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for appetite regulation, metabolic signaling, body composition, and energy-related pathways. Unlike Tirzepatide, which targets GLP-1 and GIP, Mazdutide combines GLP-1 with glucagon receptor activity.
Mazdutide is a GLP-1/glucagon dual receptor agonist developed by Innovent in China under a licence from Lilly. It received NMPA approval in June 2025 for long-term weight management in adults with overweight or obesity and later received a second approval in September 2025 for glycaemic control in adults with type 2 diabetes.
For a dedicated mechanism review, see our Mazdutide Peptide Research Guide.
Zenagamtide (Formerly Amycretin)
Zenagamtide, formerly known as amycretin, is Novo Nordisk’s unimolecular GLP-1 and amylin receptor agonist. Novo Nordisk initiated its AMAZE Phase 3 obesity programme in Q1 2026, while Phase 3 development in type 2 diabetes was also planned following positive Phase 2 results.
Zenagamtide is discussed here for clinical-development context and is not presented as an APS research product.
Survodutide
Survodutide is an investigational glucagon/GLP-1 receptor dual agonist being developed by Boehringer Ingelheim. It is being evaluated in global Phase 3 obesity programmes including SYNCHRONIZE-1 and SYNCHRONIZE-2, with additional late-stage research in metabolic liver disease and cardiovascular-risk populations.
MariTide
MariTide (maridebart cafraglutide) is not a conventional unimolecular peptide agonist. It is an antibody–peptide conjugate designed to activate the GLP-1 receptor while antagonising the GIP receptor. Amgen’s MARITIME Phase 3 programme includes chronic weight management, cardiovascular outcomes, sleep apnoea and other obesity-related settings.
Clinical Development Status in 2026
Some next generation obesity peptides are already approved in certain markets, while others remain in Phase 3 or earlier development. This distinction matters because it helps readers understand which compounds have the most clinical data and which are still emerging.
| Peptide | Mechanism | Development |
| Tirzepatide | GLP-1 + GIP | Approved in multiple markets for specified indications |
| Retatrutide | GLP-1 + GIP + glucagon | Phase 3; pivotal results reported |
| Mazdutide | GLP-1 + glucagon | Approved in China for adult weight management and type 2 diabetes; additional studies ongoing |
| Survodutide | GLP-1 + glucagon | Phase 3 |
| MariTide | GLP-1R agonism + GIPR antagonism | Phase 3 MARITIME programme ongoing |
| Zenagamtide | GLP-1 + amylin | Phase 3 obesity programme initiated in Q1 2026 |
The programmes are at different stages. Tirzepatide has regulatory approvals in multiple markets; mazdutide has approvals in China; retatrutide has reported pivotal Phase 3 results but remains investigational; survodutide, MariTide and zenagamtide remain in Phase 3 development.
What Late-Stage Clinical Research Has Reported
Clinical trials have reported that next generation obesity peptides may influence several areas of metabolic research, including appetite regulation, weight-related outcomes, body composition, glycaemic markers, and cardiometabolic measures.
Researchers observed substantial weight-related outcomes in Retatrutide studies, including the recent TRIUMPH-1 Phase 3 findings. Clinical trials also reported meaningful results for Tirzepatide, Mazdutide, and Survodutide, although direct comparisons between compounds should be made carefully because study designs, populations, durations, and endpoints differ.
Cross-trial percentages should not be interpreted as head-to-head rankings because populations, estimands, dose strategies and trial durations differ.
Researchers are increasingly measuring fat mass, lean mass, waist circumference, glycaemic markers, blood pressure, lipid measures and clinical outcomes in addition to total body weight.
What Are Researchers Learning From Triple Agonists?
Triple agonists allow researchers to examine coordinated GIP, GLP-1 and glucagon receptor activity within a single molecule. Retatrutide has provided late-stage clinical evidence for this approach, but triple agonism should not be assumed to be inherently superior to every dual or alternative multi-target strategy.
However, several questions remain. Researchers still need more long-term safety data, real-world evidence, head-to-head comparisons, and durability studies. It is also important to understand whether stronger outcomes come with different tolerability considerations.
For now, triple agonists remain one part of an evolving research landscape.
What Researchers Still Don’t Know
Despite rapid progress, next generation obesity peptide research still has unanswered questions.
Researchers continue to investigate:
- Long-term safety outcomes
- How trial outcomes translate after regulatory approval and broader clinical use
- Head-to-head comparisons between compounds
- Durability after treatment discontinuation
- Effects on lean mass and body composition
- Cardiometabolic outcomes
- Cost and access considerations
- Differences between patient populations
This uncertainty is important. Early clinical results can be promising, but long-term research is needed to understand how these compounds perform across broader populations and real-world settings.
Adjacent Metabolic Peptide Research
MOTS-C is a mitochondrial-derived peptide studied in metabolic and energy-sensing pathways. It is not part of the same clinical obesity-drug pipeline as retatrutide, survodutide, mazdutide, MariTide or zenagamtide.
See our MOTS-C Peptide Research Guide.
Which Compounds Does APS Cover in Research Content?
APS publishes research-focused guides covering retatrutide, tirzepatide, mazdutide, MOTS-C and AOD-9604. These compounds differ in mechanism, evidence level and regulatory context and should not be treated as equivalent members of a single therapeutic class.
Survodutide, MariTide and zenagamtide are discussed for scientific and clinical-development context only and are not presented here as APS research products.
APS materials are supplied strictly for laboratory and scientific research and are not intended for human or veterinary administration.
Why Research Quality Matters
For laboratory materials, compound identity and analytical documentation should be evaluated separately from the clinical evidence generated with regulated pharmaceutical formulations.
Key quality signals include:
- Batch-specific COA
- Identity testing
- Analytical purity method
- Lot traceability
- Storage information
- Clear research-use classification
For further reading, see our Certificate of Analysis Guide, Peptide Purity Explained and Research Peptides Australia Guide.
View Certificates of Analysis for Research Materials →
Explore Research Peptide Guides →
FAQs
What are next generation obesity peptides?
The term generally refers to newer metabolic compounds that move beyond GLP-1-only activity by combining pathways such as GIP, glucagon or amylin, or by using alternative multi-target molecular designs.
What comes after GLP-1 therapies?
Current research includes dual receptor agonists, triple receptor agonists and alternative multi-target strategies such as GLP-1/amylin agonism and GLP-1 agonism combined with GIP receptor antagonism.
Which Next-Generation Obesity Compounds Are in Late-Stage Development in 2026?
Retatrutide, survodutide, MariTide and zenagamtide all have Phase 3 programmes in 2026, while mazdutide has already received approvals in China for adult weight management and type 2 diabetes.
Is Retatrutide a triple agonist?
Yes. Retatrutide is classified as a triple agonist peptide because it simultaneously activates three receptor pathways: GLP-1, GIP and glucagon. This distinguishes it from dual agonists such as Tirzepatide and Mazdutide.
How is Retatrutide different from Tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors, whereas retatrutide also activates the glucagon receptor. This creates a different receptor profile, but cross-trial efficacy comparisons should not be treated as head-to-head evidence.
What Is Zenagamtide (Formerly Amycretin)?
Zenagamtide is Novo Nordisk’s unimolecular GLP-1 and amylin receptor agonist, formerly known as amycretin. Its Phase 3 AMAZE obesity programme began in Q1 2026.
Which obesity peptides are in Phase 3?
As of September 2026, Phase 3 programmes include retatrutide, survodutide, MariTide and zenagamtide. Development status can change rapidly, so this section should be reviewed periodically.
Are These Compounds Approved Therapeutic Products in Australia?
Regulatory status differs by compound and jurisdiction. Several programmes discussed here remain investigational, while approvals in markets such as China do not imply TGA approval in Australia. Regulatory status should be checked for the exact medicine and indication.
Why are researchers interested in multi-pathway peptides?
Researchers believe obesity is influenced by multiple interconnected biological systems rather than a single hormone pathway. Multi-pathway peptides allow scientists to investigate how appetite regulation, nutrient sensing, metabolism, and energy expenditure interact, providing a broader understanding of metabolic biology than single-target compounds alone.
What is the future of obesity peptide research?
Research is expanding across triple agonism, GLP-1/glucagon dual agonism, GLP-1/amylin biology, longer-acting molecular designs and head-to-head outcome studies. Key unresolved questions include long-term safety, durability, body composition and clinical outcomes beyond weight.
Is MariTide a Peptide?
MariTide is more accurately described as an antibody–peptide conjugate. It combines GLP-1 receptor agonism with GIP receptor antagonism and is therefore structurally different from unimolecular peptide agonists such as retatrutide.
Is Mazdutide Still Investigational?
Not for all uses in China. Mazdutide received Chinese regulatory approval for adult weight management in June 2025 and later for glycaemic control in adults with type 2 diabetes, while additional studies and indications continue.
